Mundipharma supports new prostate cancer research

Medical oncologist and clinical research fellow Angelyn Anton has been awarded the 2019 Mundipharma ANZUP Uro-Oncology Clinical Research Fellowship.

This provides Dr Anton with $60,000 to support her research into prostate cancer.

This is the sixth annual Clinical Research Fellowship to be awarded in partnership with the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) to support genitourinary cancer research.

Prostate cancer is the most commonly diagnosed cancer in Australian males, with one in six men expected to be diagnosed before the age of 85. It is also the third most common cause of cancer death.

Dr Anton was announced as the recipient of the fellowship at the 2019 ANZUP annual scientific meeting in Brisbane.

The fellowship is intended for early and mid-career clinician-researchers of any healthcare discipline in genitourinary cancer research and provides funding for one year to the institution of the successful applicant.

Dr Anton said her research primarily involved the use of real world data to examine current treatment patterns and outcomes in prostate cancer.

Jane Orr, Managing Director of Mundipharma in Australia and New Zealand, said: “Dr Anton’s research is focussed on comparing rates of cognitive decline in elderly prostate cancer patients receiving novel antiandrogens.

“This research will provide relevant and valuable data to inform future decision making, influence current clinical practice and ultimately improve patient outcomes.

“Dr Anton has a remarkable drive to help improve clinical practice and this Fellowship will help her reach that potential,” said Jane Orr, Managing Director of Mundipharma in Australia and New Zealand.

ANZUP Chair Professor Ian Davis said Dr Anton was very deserving of this recognition.

“The Mundipharma ANZUP Uro-oncology Clinical Research Fellowship has supported some of Australia’s best and brightest emerging clinician-researchers, and Dr Anton is the latest addition to that eminent group,” Professor Davis said.

“She has already proven her capability and submitted a very competitive application that stood out amongst many other excellent applicants. ANZUP is glad to be able to provide this fellowship to her, with the generous support of Mundipharma.”

According to Dr Anton, the fellowship has provided a significant opportunity to further her  clinical research goals and to support the REAL-Pro study, the first prospective registry-based randomised clinical trial in prostate cancer.

The fellowship was previously awarded by Tolmar Australia, which was acquired by Mundipharma in 2018, along with exclusive Australian and New Zealand distribution rights for two prostate cancer medications.

Must Read

A new pathway to improved traumatic brain injury

A team of Australian researchers have developed a ‘new dictionary’ to better predict outcomes for people who have experienced traumatic brain injury (TBI). The Australian...